No Data
No Data
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Arcus Biosciences (RCUS) and Maravai Lifesciences Holdings (MRVI)
Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript
Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript
Arcus Biosciences Q1 2024 GAAP EPS $(0.05) Beats $(0.98) Estimate, Sales $145.000M Beat $33.862M Estimate
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.98) by 94.9 percent. This is a 95.41 percent increase over losses of $(1.0
Express News | Arcus Biosciences Inc -Well-Positioned to Advance Full Pipeline With $1.1 Bln in Cash, Cash Equivalents and Marketable Securities and Runway Into 2027
Arcus Biosciences | 10-Q: Quarterly report
Arcus Biosciences 1Q Rev $145M >RCUS
Arcus Biosciences 1Q Rev $145M >RCUS